Latest Conference Articles

Novel PDE4B Inhibitor Slows Lung Function Decline in IPF: Phase 2 Data from Boehringer Ingelheim

Novel PDE4B Inhibitor Slows Lung Function Decline in IPF: Phase 2 Data from Boehringer Ingelheim

May 17th 2022

ATS

ATS 2022: The investigational PDE4B inhibitor slowed pulmonary decline in patients with IPF, both alone and with background use of approved antifibrotics.

NAVIGATOR Data Presented at ATS 2022 Show Improved Clinical Responses to Treatment with Tezepelumab vs Placebo

NAVIGATOR Data Presented at ATS 2022 Show Improved Clinical Responses to Treatment with Tezepelumab vs Placebo

May 16th 2022

ATS

ATS 2022. A greater proportion of tezepelumab-treated patients with severe, uncontrolled asthma achieved on-treatment clinical responses than placebo-treated patients.

Novel Fixed-dose Albuterol-Budesonide Inhaler Significantly Reduced Exacerbation Risk in Severe Asthma

Novel Fixed-dose Albuterol-Budesonide Inhaler Significantly Reduced Exacerbation Risk in Severe Asthma

May 16th 2022

ATS

ATS 2022: A fixed dose SABA/corticosteroid combination reduced risk of exacerbation by 27% vs SABA alone in the MANDALA study.

Objective Confirmation of Asthma Diagnosis Often Missing in Primary Care, Study Suggests

Objective Confirmation of Asthma Diagnosis Often Missing in Primary Care, Study Suggests

May 14th 2022

ATS

ATS 2022: Charts from an EHR that included a suspected diagnosis of asthma either had no objective documentation or mentioned a test but included no results.

SuperWIN Retail Nutrition Counseling Study Coauthor Unpacks Findings that Surprised Him

SuperWIN Retail Nutrition Counseling Study Coauthor Unpacks Findings that Surprised Him

April 25th 2022

ACC

Dylan Steen, MD talks about several SuperWIN results that caught him happily by surprise and suggest plenty of room for follow-up research.

Expanding Reach Beyond Clinic Walls is Essential to the Future of Health Care, says Investigator

Expanding Reach Beyond Clinic Walls is Essential to the Future of Health Care, says Investigator

April 15th 2022

ACC

SuperWIN trial findings suggest the future of successful health care depends on harnessing familiar, community- based resources to maintain health and deliver care.

SuperWIN Trial of Retail-based Dietary Interventions Wins on Many Levels: Dylan Steen, MD, Explains

SuperWIN Trial of Retail-based Dietary Interventions Wins on Many Levels: Dylan Steen, MD, Explains

April 14th 2022

ACC

Coprincipal investigator Steen highlights the first-of-its kind study and the findings—local in-store dietitian counseling/feedback, nutrition education, and online shopping savvy improve food choices, health metrics.

Antihypertensive Treatment during Pregnancy Linked to Better Outcomes, According to New NIH Study

Antihypertensive Treatment during Pregnancy Linked to Better Outcomes, According to New NIH Study

April 8th 2022

ACC

ACC 2022: Use of antihypertensive therapy in pregnant women was associated with better pregnancy outcomes, such as preeclampsia and fetal or neonatal death.

Sotagliflozin Reduced MACE Risk in Patients With and Without Prior CVD, in New Analysis of SCORED Clinical Trial

Sotagliflozin Reduced MACE Risk in Patients With and Without Prior CVD, in New Analysis of SCORED Clinical Trial

April 5th 2022

ACC

ACC 2022: Updated findings further highlight benefit of sotagliflozin treatment in patients with T2D and CKD, regardless of cardiovascular disease presence.

Reduced Dietary Sodium in Heart Failure Patients Had Little Impact on Clinical Events: SODIUM-HF

Reduced Dietary Sodium in Heart Failure Patients Had Little Impact on Clinical Events: SODIUM-HF

April 2nd 2022

ACC

ACC 2022. SODIUM-HF secondary findings, however, showed improvement in NYHA HF class and in QOL in the dietary intervention group.